The Phase II trial sponsored by Biogipuzkoa Health Research Institute aims to evaluate a novel combination therapy for ALS, a market characterized by high unmet medical need and limited treatment options. If successful, this combination could position itself competitively against existing therapies like Riluzole and Edaravone, potentially capturing a share of the growing ALS treatment market. The trial's design includes an open-label extension, which may facilitate further data collection and patient retention, enhancing the asset's value. The trial's outcomes could also support future regulatory filings and partnerships, particularly if the combination demonstrates significant clinical efficacy and safety.